title: Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain.
abstract: Many efficacy endpoints have been used in clinical trials of acute migraine pharmacotherapy. Headache response or headache relief (i.e., moderate/severe pain reduced to mild/no pain) at a single, specified time-point, traditionally the primary endpoint, and headache recurrence (i.e., return of pain after initial postdose relief) are inadequate. Headache relief does not provide information about pain-free response and counts a partial response as a treatment success. Headache recurrence can reflect sustained efficacy but is confounded by initial response to treatment, because ineffective drugs have low recurrence rates. The International Headache Society (IHS) guidelines state that 2 hour pain-free response and sustained pain-free response (i.e., freedom from pain with no recurrence or use of rescue or study medication 2-24 hours postdose) provide the most clinically relevant information about the efficacy of migraine pharmacotherapy. The pain-free criterion counts partial responses as failures and thus is a more rigorous test of therapeutic benefit than headache relief, and the two endpoints together incorporate the main treatment attributes that determine patient satisfaction. As an example, consider needle-free subcutaneous sumatriptan and oral triptan tablets. An open-label study of needle-free subcutaneous sumatriptan by Cady and colleagues found that 2 hour pain-free response and sustained pain-free response were 64% and 42% respectively. For oral triptan tablets, the 2001 metaanalysis by Ferrari and colleagues reported 2 hour pain-free response rates ranging from 23% to 38% and sustained pain-free response rates ranging from 11% to 26%. The measures of pain-free response 2 hours postdose and sustained pain-free response can differentiate among treatments and be used to guide therapeutic choices.
authors.affiliation: Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. stephen.silberstein@jefferson.edu
authors.forename: S D
authors.initials: SD
authors.lastname: Silberstein
authors.forename: L C
authors.initials: LC
authors.lastname: Newman
authors.forename: M J
authors.initials: MJ
authors.lastname: Marmura
authors.forename: S J
authors.initials: SJ
authors.lastname: Nahas
authors.forename: S J
authors.initials: SJ
authors.lastname: Farr
mesh_terms: D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D059408:Pain Management; D010147:Pain Measurement; D017060:Patient Satisfaction; D012107:Research Design; D058825:Serotonin 5-HT1 Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D058825:Serotonin 5-HT1 Receptor Agonists; D018170:Sumatriptan